FDA Brief

Warning letters Drugs

FDA warning letter to

Pharmaplast S.A.E.

High riskIssued Apr 13, 2023Posted Apr 25, 2023Center for Drug Evaluation and Research | CDER

FDA cited Pharmaplast S.A.E. for failing to test drug components, including glycerin and ethanol, for dangerous contaminants.

What happened

FDA inspected Pharmaplast S.A.E.'s Alexandria drug manufacturing facility from November 6 to November 10, 2022. It found the firm did not test each component lot for identity and did not test ethanol for methanol or ensure glycerin was tested for diethylene glycol (DEG) or ethylene glycol (EG). It also found cleaning validation did not include transfer carriage vessels used to move drug and device components, creating a cross-contamination risk.

What FDA found

  1. The firm failed to test each incoming component lot for identity and conformity with specifications and failed to validate supplier test results.

    21 CFR 211.84(d)(1) and (2)
  2. The firm did not test ethanol for methanol or ensure glycerin was tested for diethylene glycol (DEG) or ethylene glycol (EG).

    21 CFR 211.84(d)(1) and (2)
  3. The firm's cleaning and maintenance procedures did not cover all product-contact equipment, including transfer carriage vessels.

    21 CFR 211.67(b)

What FDA wants

FDA asks the firm to correct the violations promptly and respond in writing within 15 working days, including plans and results for component testing, DEG/EG and methanol testing, cleaning validation, and risk assessments for affected U.S. products.

Who should pay attention

  • companies that rely on this contract manufacturer for finished drugs
  • drugmakers using glycerin or ethanol in products
  • quality teams responsible for supplier verification and incoming testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  2. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. VeganicSKN Limited

    FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.

    High risk